Abrilada vs. Rinvoq

Abrilada (adalimumab-afzb) and Rinvoq (upadacitinib) are used to treat rheumatoid arthritis.

Abrilada is also used to treat juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.

Rinvoq is used in adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Abrilada is biosimilar to Humira (adalimumab).

Abrilada and Rinvoq belong to different drug classes. Abrilada is a tumor necrosis factor (TNF) blocker and Rinvoq is a Janus kinase (JAK) inhibitor.

Side effects of Abrilada and Rinvoq that are similar include infections (e.g. upper respiratory, sinusitis).

Side effects of Abrilada that are different from Rinvoq include injection site reactions, headache, and rash.

Side effects of Rinvoq that are different from Abrilada include nausea, cough, and fever.

Both Abrilada and Rinvoq may interact with live vaccines.

Abrilada may also interact with abatacept, anakinra, warfarin, cyclosporine, and theophylline.

Rinvoq may also interact with strong CYP3A4 inhibitors (e.g., ketoconazole) and strong CYP3A4 inducers (e.g., rifampin).

Side effects of Abrilada include:

• Infections (e.g. upper respiratory, sinusitis),
• injection site reactions,
• headache, and
• rash

Common side effects of Rinvoq include:

• upper respiratory tract infections,
• nausea,
• cough, and
• fever

Abrilada (adalimumab-afzb) is a tumor necrosis factor (TNF) blocker used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis. Abrilada is biosimilar to Rinvoq (adalimumab).

Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Abrilada may interact with other medicines such as:

• abatacept,
• anakinra,
• warfarin,
• cyclosporine,
• theophylline, and
• live vaccines

Tell your doctor all medications and supplements you use and all vaccines you recently received.

Rinvoq may interact with strong CYP3A4 inhibitors (e.g., ketoconazole), strong CYP3A4 inducers (e.g., rifampin), and live vaccines. Tell your doctor all medications and supplements you use. Rinvoq is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Rinvoq and for 4 weeks following completion of therapy. It is unknown if Rinvoq passes into breast milk. Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with Rinvoq, and for 6 days after the last dose.

The dose of Abrilada to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis is 40 mg every other week. The dose of Abrilada to treat juvenile idiopathic arthritis in children is based on the child's body weight. The initial dose (Day 1) of Abrilada to treat adult Crohn's disease and ulcerative is 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two consecutive days). The second dose two weeks later (Day 15) is 80 mg. Two weeks later (Day 29), begin a maintenance dose of 40 mg every other week. The dose of Abrilada to treat plaque psoriasis is 80 mg initial dose, followed by 40 mg every other week starting one week after the initial dose.

The recommended dose of Rinvoq is 15 mg once daily. Rinvoq may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.